BINEX Co., Ltd.
Financials
Valuation Metrics
BINEX Co., Ltd.'s Market Cap is ₩2023B. At end of 2025 it was ₩4896B. Ranked #851 of 2,421 in KR market (top 35%), #397 of 1,640 on KOSDAQ (top 24%), #90 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 202.32B KRW | KR#851/2,421 Sec#90/231 |
| Revenue | 157.28B KRW | KR#1,148/2,421 Sec#70/231 |
| Net Income | -29.33B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 311.42B KRW | KR#1,012/2,421 Sec#65/231 |
| Net Assets | 187.46B KRW | KR#989/2,421 Sec#70/231 |
| Employees | 671 | KR#374/2,421 Sec#31/231 |
| Value | ||
| P/B | 1.08x | KR#1,534/2,421 Sec#98/231 |
| P/S | 1.29x | KR#1,549/2,421 Sec#89/231 |
| Profitability | ||
| ROE | -15.64% | KR#2,031/2,421 Sec#155/231 |
| ROA | -9.42% | KR#2,088/2,421 Sec#156/231 |
| Op. Margin | -15.40% | KR#2,077/2,421 Sec#141/231 |
| Revenue Growth | 2.68% | KR#1,339/2,421 Sec#133/231 |
| Financial Health | ||
| Debt Ratio | 66.13% | KR#1,171/2,421 Sec#142/231 |
| Total Debt | 91.87B KRW | KR#759/2,421 Sec#47/231 |
| Cash | 18.36B KRW | KR#1,298/2,421 Sec#100/231 |
| Current Ratio | 1.33x | KR#1,352/2,421 Sec#143/231 |
| Performance | ||
| 1Y Return | -62.85% | KR#2,236/2,421 Sec#210/231 |
| 1M Return | -5.78% | KR#1,857/2,421 Sec#150/231 |
| From 52W High | -67.18% | KR#2,121/2,421 Sec#174/231 |
| 1Y MDD | -67.87% | KR#1,889/2,421 Sec#160/231 |
| Trading | ||
| Volume | 83,140 shares | KR#872/2,421 Sec#86/231 |
| Trading Value | 516.4M KRW | KR#913/2,421 Sec#91/231 |
| Foreign Own. | 7.44% | KR#600/2,421 Sec#49/231 |
| Per Share | ||
| EPS | -897 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,735 KRW | KR#1,391/2,421 Sec#99/231 |
Company Info
Established in 1957, the company changed its name to Binex in 2000, listed on KOSDAQ in 2001, and expanded its business in 2015. It operates chemical pharmaceutical manufacturing and biopharmaceutical CDMO businesses, producing over 120 products in Busan and providing CDMO services in Songdo and Osong. To advance as a global CDMO, the company has passed GMP audits and plans to obtain cGMP certification and expand production capacity through an FDA audit in 2025, solidifying its standing as a global bio hub. Binex is headquartered in Saha-gu, Busan.